← Back to Search

Partial VEPMP Intervention for Pneumonia

N/A
Waitlist Available
Led By Mohsen Bazargan, PhD
Research Sponsored by Charles Drew University of Medicine and Science
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Parishioner at a church receiving the VEPMP intervention
Identify as African American or Latinx
Timeline
Screening 3 weeks
Treatment Varies
Follow Up intervention: 12 months; follow-up point: 9 & 18 months post-intervention
Awards & highlights

Study Summary

This study is evaluating whether a community-based intervention can help increase vaccination rates for underserved populations.

Eligible Conditions
  • Influenza
  • Pneumonia
  • Coronavirus
  • Vaccine Refusal

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intervention: 12 months; follow-up point: 9 & 18 months post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and intervention: 12 months; follow-up point: 9 & 18 months post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report
Secondary outcome measures
Percentage of Participants Achieving Adherence to COVID-19, influenza, and pneumonia vaccination schedules Risk Using the NIH Toolbox Surveys on COVID-19
Percentage of Participants Achieving Decreased Levels of COVID-19, influenza, and pneumonia Mistrust and Barriers Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia
Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19, influenza, and pneumonia Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia

Trial Design

3Treatment groups
Experimental Treatment
Group I: Arm 3Experimental Treatment1 Intervention
This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan following completion of Arm 1 and 2.
Group II: Arm 2Experimental Treatment1 Intervention
This arm will include 5 churches who will receive some study activities in the Vaccine Education Promotion Management Plan
Group III: Arm 1Experimental Treatment1 Intervention
This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan

Find a Location

Who is running the clinical trial?

Charles Drew University of Medicine and ScienceLead Sponsor
51 Previous Clinical Trials
6,637 Total Patients Enrolled
1 Trials studying Pneumonia
600 Patients Enrolled for Pneumonia
Mohsen Bazargan, PhDPrincipal InvestigatorCharles R. Drew University of Medicine & Science
2 Previous Clinical Trials
150 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Oct 2026